Industry
An analytical laboratory serving the research-chemical sector reports rising failure rates across client samples.
One of the higher-volume analytical laboratories serving the peptide sector said this week that the share of client samples failing purity specifications has risen for a third consecutive quarter — a signal consistent with our own independent testing data.
The laboratory attributes the trend to demand outpacing legitimate synthesis capacity, pulling lower-grade material into the supply chain. Our 2026 testing cycle found the widest purity spread we have measured: 61% to 99.2% across 20 samples.
Apex Peptides holds the top position; Cascade Research Group drops 17 points after failed verification; BioRegen enters the top five.
RankingsAngiogenesis modulation, growth-factor signaling, and the gaps between rodent data and human claims.
ScienceThe August guidance clarifies bulk-substance eligibility and signals enforcement priorities for the next year.
RegulationThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
